Evidence map›Paper›PMID 28584176›Full record

ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2017

One Health contributions towards more effective and equitable approaches to health in low- and middle-income countries.

S Cleaveland, J Sharp, B Abela-Ridder, K J Allan, J Buza, J A Crump, A Davis, V J Del Rio Vilas, W A de Glanville, R R Kazwala and 10 more

Open access · hybridAbstract readReview
In one paragraph

Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 2 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 2 syntheses or guidelines pooled it, 213 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Metagenomic next-generation sequencing: new horizons in microbiology.Frontiers in cellular and infection microbiology · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Evidence ofNew microbes and new infections · 2025
    Review
  18. Article
  19. Article
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 6 countries.

S CleavelandBoyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health and Comparative Medicine, and sarah.cleaveland@glasgow.ac.uk.ORCID http://orcid.org/0000-0002-0456-0959
J SharpSchool of Geographical and Earth Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
B Abela-RidderDepartment for the Control of Neglected Tropical Diseases, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland.
K J AllanBoyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health and Comparative Medicine, and.
J BuzaSchool of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science and Technology, PO Box 447, Arusha, Tanzania.
J A CrumpCentre for International Health, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
A DavisSchool of Geographical and Earth Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
V J Del Rio VilasSchool of Veterinary Medicine, University of Surrey, Guildford GU2 7XH, UK.
W A de GlanvilleBoyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health and Comparative Medicine, and.
R R KazwalaCollege of Veterinary Medicine and Medical Sciences, Sokoine University of Agriculture, PO Box 3105, Morogoro, Tanzania.
T KibonaSchool of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science and Technology, PO Box 447, Arusha, Tanzania.
F J LankesterPaul G. Allen School for Global Animal Health, Washington State University, Pullman, WA 99164, USA.
A LugeloCollege of Veterinary Medicine and Medical Sciences, Sokoine University of Agriculture, PO Box 3105, Morogoro, Tanzania.
B T MmbagaKilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, PO Box 2236, Moshi, Tanzania.
M P RubachDivision of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA.
E S SwaiMinistry of Agriculture, Livestock and Fisheries, PO Box 9152, Dar es Salaam, Tanzania.
L WaldmanInstitute for Development Studies, Library Road, Brighton BN1 9RE, UK.
D T HaydonBoyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health and Comparative Medicine, and.
K HampsonBoyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health and Comparative Medicine, and.
J E B HallidayBoyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health and Comparative Medicine, and.ORCID http://orcid.org/0000-0002-1329-9035
Département Santé Animale · FRNelson Mandela African Institution of Science and Technology · TZSokoine University of Agriculture · TZUniversity of Glasgow · GBDuke Medical Center · USInstitute of Development Studies · GBKilimanjaro Christian Medical Centre · TZMinistry of Livestock and Fisheries · TZUniversity of Otago · NZUniversity of Surrey · GBWashington State University · USWorld Health Organization · CH

Funding

Investigating Febrile Deaths in Tanzania (INDITe)R01AI121378 · NIAID · DUKE UNIVERSITY · PI RUBACH, MATTHEW P · 2016 to 2020
$2.7M
Viral Zoonoses and Severe Febrile Illness in Northern TanzaniaK23AI116869 · NIAID · DUKE UNIVERSITY · PI RUBACH, MATTHEW P · 2016 to 2020
$896k
Biotechnology and Biological Sciences Research Council BB/J010367/1Biotechnology and Biological Sciences Research Council BB/L018845/1Biotechnology and Biological Sciences Research Council BB/L018926/1NIAID NIH HHS K23 AI116869NIAID NIH HHS R01 AI121378Wellcome Trust 207569/Z/17/ZWorld Health Organization 001
6 · The paper itself

Abstract

Emerging zoonoses with pandemic potential are a stated priority for the global health security agenda, but endemic zoonoses also have a major societal impact in low-resource settings. Although many endemic zoonoses can be treated, timely diagnosis and appropriate clinical management of human cases is often challenging. Preventive 'One Health' interventions, e.g. interventions in animal populations that generate human health benefits, may provide a useful approach to overcoming some of these challenges. Effective strategies, such as animal vaccination, already exist for the prevention, control and elimination of many endemic zoonoses, including rabies, and several livestock zoonoses (e.g. brucellosis, leptospirosis, Q fever) that are important causes of human febrile illness and livestock productivity losses in low- and middle-income countries. We make the case that, for these diseases, One Health interventions have the potential to be more effective and generate more equitable benefits for human health and livelihoods, particularly in rural areas, than approaches that rely exclusively on treatment of human cases. We hypothesize that applying One Health interventions to tackle these health challenges will help to build trust, community engagement and cross-sectoral collaboration, which will in turn strengthen the capacity of fragile health systems to respond to the threat of emerging zoonoses and other future health challenges. One Health interventions thus have the potential to align the ongoing needs of disadvantaged communities with the concerns of the broader global community, providing a pragmatic and equitable approach to meeting the global goals for sustainable development and supporting the global health security agenda.This article is part of the themed issue 'One Health for a changing world: zoonoses, ecosystems and human well-being'.

Indexed as

Developing CountriesGlobal HealthOne HealthAnimalsHumansZoonosesglobal healthhealth equityOne Healthpovertysustainable developmentzoonoses

Identifiers

PMID28584176
PMCPMC5468693
OpenAlexW2613351520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.